Regeneron Pharmaceuticals Inc (REGN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have been given an average recommendation of “Hold” by the twenty-three ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $409.80.

A number of equities research analysts recently commented on the company. TheStreet raised Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Guggenheim raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price objective for the company in a research note on Friday, January 4th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price objective for the company in a research note on Thursday, February 7th. BidaskClub cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 7th. Finally, Cowen reaffirmed a “hold” rating and set a $385.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, January 7th.

In other news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 12.42% of the company’s stock.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its holdings in Regeneron Pharmaceuticals by 1.1% during the fourth quarter. BlackRock Inc. now owns 5,929,225 shares of the biopharmaceutical company’s stock worth $2,214,564,000 after acquiring an additional 67,241 shares in the last quarter. Vanguard Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after acquiring an additional 75,868 shares in the last quarter. Vanguard Group Inc raised its holdings in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after acquiring an additional 75,868 shares in the last quarter. FMR LLC raised its holdings in Regeneron Pharmaceuticals by 6.6% during the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after acquiring an additional 330,875 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock worth $402,138,000 after acquiring an additional 78,143 shares in the last quarter. Institutional investors own 66.97% of the company’s stock.

Shares of Regeneron Pharmaceuticals stock traded down $7.36 during midday trading on Monday, hitting $375.58. 15,102 shares of the company were exchanged, compared to its average volume of 620,441. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.47 and a quick ratio of 3.67. Regeneron Pharmaceuticals has a 52 week low of $281.89 and a 52 week high of $442.00. The company has a market capitalization of $41.73 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.53 and a beta of 1.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the previous year, the company posted $5.23 EPS. The business’s revenue for the quarter was up 21.9% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals will post 19.92 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: The role of implied volatility with call option volume

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.